A Non-inferiority Open-labelled Crossover Randomized Controlled Trial, of Two Arms, to Investigate the Adhesiveness and Safety of Rotigexole 8 mg/24 Hours Transdermal Patch, Manufactured by Eva Pharma, Egypt, Compared to the Innovator Product, Neupro® 8 mg/ 24 Hours Transdermal Patch, Manufactured by UCB Pharma S.A., Belgium, After 24 Hours of Application

A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the innovator product, Neupro® 8 mg/ 24 hours transdermal patch, manufactured by UCB Pharma S.A., Belgium, after 24 hours of application

Start Date01 Sep 2025

Sponsor / Collaborator

EVA Pharma for Pharmaceuticals & Medical Appliances SAE

CTR20252354

/ CompletedNot Applicable

罗替高汀贴片人体生物等效性研究

[Translation] Bioequivalence study of rotigotine patch in human body

本试验旨在研究单次空腹使用北京亚宝生物药业有限公司生产的罗替高汀贴片（4.5 mg/10 cm2）的药代动力学特征；以UCB Pharma S.A.持证、生产的罗替高汀贴片〔Neupro®，4.5 mg/10 cm2（释药量2 mg/24 h）〕为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性，并考察受试制剂和参比制剂在用药过程中的安全性、粘附性和皮肤刺激性。

[Translation]

The aim of this study was to investigate the pharmacokinetic characteristics of a single fasting dose of rotigotine patch (4.5 mg/10 cm2) produced by Beijing Yabao Biopharmaceutical Co., Ltd.; using the rotigotine patch (Neupro®, 4.5 mg/10 cm2 (drug release 2 mg/24 h)) licensed and produced by UCB Pharma S.A. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, to evaluate the bioequivalence of the two preparations in humans, and to investigate the safety, adhesion, and skin irritation of the test preparation and the reference preparation during medication.

Start Date01 Jul 2025

Sponsor / Collaborator

Hangzhou Hekang Pharmaceutical Co., Ltd.

NCT06291116

/ Not yet recruitingPhase 2IIT

Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease linked to mutation of the PKD1 or PKD2 genes encoding polycystins 1 and 2. Patients develop renal cysts with progressive impairment of renal function leading to renal failure. terminal renal failure for 1/3 of them. These patients also present early with high blood pressure and cardiovascular complications, notably intracerebral aneurysms. This phenotype is linked to abnormal polycystins on the cilia of renal epithelial and vascular endothelial cells which no longer ensure the mechanotransduction of shear forces linked to urinary and blood flow leading to the modification of numerous cellular functions.
Experimental results suggested that stimulation of dopamine receptor type 5 (DR5) could restore the mechanosensitivity of endothelial cells, a hypothesis supported by our first results showing that local administration of dopamine improves endothelial function in patients with ADPKD. through restoration of endothelial NO release upon increased blood flow. Similar positive results on endothelial function and hemodynamics were recently obtained in the IMPROVE-PKD study with rotigotine, a dopamine agonist administered via transdermal patches for 2 months at a low dose (4 mg/24h).
Dopaminergic stimulation could also prevent abnormalities linked to polycystin deficiency at the renal level and we therefore hypothesize that rotigotine could slow the progression of ADPKD both at the renal and cardiovascular levels.
This phase 2 study aims to ensure the good long-term tolerance of rotigotine in patients with ADPKD and to collect preliminary data on its renal impact.

Start Date01 Jan 2025

Sponsor / Collaborator-

100 Clinical Results associated with Rotigotine

100 Translational Medicine associated with Rotigotine

100 Patents (Medical) associated with Rotigotine

789

Literatures (Medical) associated with Rotigotine

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

The dopamine receptor agonist rotigotine attenuated indomethacin-induced enteropathy in the small intestinal mucosa of mice

Article

Author: Han, Xinjie ; Liu, Changchang ; Zhou, Li ; Liu, Xin ; Peng, Bingyan ; Du, Wei ; Li, Ziyu ; Zhao, Yani ; Wang, Zhiyong ; Su, Tian

BACKGROUND:

Nonsteroidal anti-inflammatory drugs induced enteropathy is characterized by disruption of the epithelial barrier and immune homeostasis, resulting in symptoms such as congestion, ulcers and inflammation. Research has suggested that dopamine (DA) exerts a protective effect on the gastroduodenal and colonic mucosa. The present study aimed to explore the effect of DA on NSAID-induced injury to the small intestinal mucosa.

METHODS:

A mouse model of enteropathy induced by indomethacin (Indo, which is a commonly used NSAID) was established by gavage. The DA agonist rotigotine (Roti) was administered alone or in combination with the DA receptor 2 (DRD2) antagonist domperidone (Domp) to model mice to determine the effect of Roti and the key role of DRD2 in this effect. Bilateral vagotomy was performed to determine whether the effect of Roti was mediated by the brain‒gut axis.

RESULTS:

Roti administration attenuated small intestinal injury in Indo-induced model mice. However, Domp administration alone exacerbated this injury. Moreover, Roti mitigated small intestinal injury by increasing Occludin and zonula occludens-1 (ZO-1) expression and decreasing TNF-α and cyclooxygenase 2 (COX-2) expression. However, the effects of Roti were abrogated by Domp. In contrast to Domp, vagotomy before Indo administration did not alter the enteroprotective effects of Roti.

CONCLUSION:

The DA receptor agonist Roti attenuated Indo-induced enteropathy via peripheral DRD2 and could be a potential drug for treating NSAID-mediated enteropathy.

01 Oct 2025·TOXICOLOGY AND APPLIED PHARMACOLOGY

Pharmacodynamics, safety pharmacology and local tolerance of rotigotine behenate extended-release microspheres

Article

Author: Du, Guangying ; Wu, Mengting ; Guo, Wei ; Yu, Xin ; Yin, Zhicong ; Chen, Yumeng ; Zhu, Xiaoyin ; Tian, Jingwei ; Zhao, Xinyu ; Cen, Xiaobo ; Liang, Yuanyingzhu ; Lv, Wenjing ; Qin, Caiyi ; Liu, Wanhui

Continuous dopaminergic stimulation (CDS) is a key strategy in Parkinson's disease (PD) treatment. We developed Rotigotine Behenate Extended-Release Microspheres (RBEM), an injectable 28-day sustained-release formulation that hydrolyzes in vivo to release active rotigotine, maintaining therapeutic levels. RBEM shows improved PK profiles-longer duration and more stable drug concentrations-versus existing CDS therapies. Its monthly dosing also enhances patient compliance, potentially optimizing efficacy and safety. Thus RBEM represents a promising advance in CDS for PD. A comprehensive preclinical assessment of RBEM was conducted to support clinical trial initiation. Gi Cell-based functional assay demonstrated that Rotigotine (active metabolite) showed potent agonism at dopamine D₃ (EC₅₀ = 0.53 nM), D_2S (11.6 nM), and D_2L (21 nM) receptors. Its prodrug, rotigotine behenate, exhibited selective D_2S agonism (EC₅₀ = 42 nM). Electrophysiological assessment using manual patch clamp technique revealed that RBEM showed weak hERG inhibition (IC₅₀ = 0.12 μM) but no cardiotoxicity in 20-week primate studies. Whole-body plethysmography studies demonstrated that dose-dependent increases in respiratory rate/min volume were observed in rats (180-540 mg/kg), but not in primates. No significant CNS effects (FOB assay, SD rats) or hemolysis (rabbit erythrocytes, ≤ 227 mg/mL). Intramuscular injection caused reversible irritation attributable to PLGA excipient, consistent with marketed microsphere formulations. In summary, RBEM's pharmacological activity is mediated by rotigotine release, with a favorable preclinical safety profile supporting clinical development. Respiratory, cardiovascular, and injection-site reactions should be prioritized in clinical monitoring.

01 Oct 2025·Lancet Regional Health-Europe

Safety and efficacy of rotigotine in patients with frontotemporal dementia: a phase 2, double-blind, randomized, placebo-controlled, multicenter trial

Article

Author: Guerrera, Gisella ; Bracca, Valeria ; Mencarelli, Lucia ; Gadola, Yasmine ; Borghi, Ilaria ; Battistini, Luca ; Ludovici, Andrea ; Daniele, Antonio ; Candeo, Francesca ; Lucchini, Silvia ; Di Lorenzo, Francesco ; Pezzopane, Valentina ; Bonnì, Sonia ; Alberici, Antonella ; Koch, Giacomo ; Martorana, Alessandro ; Premi, Enrico ; Esposito, Romina ; Maiella, Michele ; Ferrari, Clarissa ; Romano, Pasquale ; Casula, Elias Paolo ; Cerulli Irelli, Emanuele ; Assogna, Martina ; Borroni, Barbara ; Ferraresi, Matteo ; D'Acunto, Alessia ; Motta, Caterina ; Bertagna, Francesco

Background:

Frontotemporal dementia (FTD) is a common form of dementia with no approved pharmacological treatment. Clinical and experimental evidence suggest that dopaminergic transmission is impaired in FTD. Here we aimed at investigating the clinical impact of treatment with dopaminergic agonists in FTD.

Methods:

This was a phase IIa 24-week randomized, double-blind, multicenter, placebo-controlled study, conducted in Italy from June 16th 2021 to April 30th 2023. Patients with a diagnosis of probable behavioral variant FTD (bvFTD) were randomly assigned in a 1:1:1 ratio to receive rotigotine transdermal patches at 4 mg/24 h, rotigotine transdermal patches at 6 mg/24 h, or placebo transdermal patches for 24 weeks. Randomization was centralized and performed using a double-blind covariate-adaptive scheme. The primary outcome was analyzed in the intention-to treat (ITT) population. The primary efficacy outcome measure was the change at 24-weeks from baseline in the Frontal Assessment Battery (FAB). The trial is completed and was registered on the clinicaltrial.gov website (NCT04937452).

Findings:

A total of 128 patients were screened, of which 75 were randomized. 25 patients were randomized to receive Rotigotine 4 mg, 26 patients to Rotigotine 6 mg, and 24 patients to placebo. The mean age of patients was 66.5 ± 8 of which 31 (41%) were female. A total of 69 patients (92%) completed the study. The estimated mean change from baseline at 24 weeks in the FAB score in the ITT population was 0.18 (95% confidence interval [CI] -0.79 to 1.15) in the rotigotine 4 mg group, 0.89 (95% CI -0.09 to 1.88) in the rotigotine 6 mg group and 1.08 (95% CI 0.19-1.98) in the placebo group (rotigotine 4 mg vs placebo, -0.90; 95% CI -2.22 to 0.42; p = 0.18; rotigotine 6 mg vs placebo, -0.19; 95% CI -1.52 to 1.14; p = 0.77). No significant effect was found on secondary outcome measures. Adverse events were mild in all groups and more common in the rotigotine (4 mg: 4/25; 6 mg: 3/26) than in the placebo (1/24) group.

Interpretation:

Rotigotine administration may not be a viable therapeutic option for enhancing frontal function, slowing disease progression, mitigating functional decline or ameliorating behavioral disturbances in bvFTD patients. The current findings provide data in a large sample of bvFTD that might be useful for the design of future clinical trials.

Funding:

This trial was funded by a joint grant from the Alzheimer Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) grant to GK and BB (GFTD-201902-2017958).

News (Medical) associated with Rotigotine

15 Sep 2025

·www.fiercepharma.com

BMS sells controlling stake in historic US-China pharmaceutical joint venture

Bristol Myers Squibb originally linked up with China’s Sinopharm Foreign Trade to establish Sino-American Shanghai Squibb Pharmaceuticals as the first U.S.-China pharmaceutical joint venture back in 1982. More than 40 years after establishing the first U.S. pharmaceutical joint venture in China, Bristol Myers Squibb is handing over its controlling stake in the business.BMS has inked an agreement to sell a 60% ownership stake in its China-based joint venture Sino-American Shanghai Squibb Pharmaceuticals (SASS), a BMS spokesperson told Fierce Pharma in an emailed statement. The move is primarily related to manufacturing of older medicines and consumer products in China and doesn't affect Bristol's core business in the country.An internal email circulating online suggests Hillhouse Capital is on the other end of the transaction. Hillhouse is one of Asia’s biggest investment firms, having invested in such biopharma outfits as BeOne Medicines (formerly BeiGene) and Jiangsu Hengrui Pharmaceuticals. The BMS spokesperson didn’t address the buyer’s identity. “As part of our long-term strategy, we continue to align our resources to support evolving business needs across our global network,” the BMS spokesperson said. “The planned sale of our interest in the SASS joint venture reflects the continued implementation of our manufacturing strategy—one that balances internal capabilities with strong external partnerships to enhance regional focus and ensure long-term supply reliability for patients in China and around the world.”BMS will work to assist any employees impacted by the deal and is prioritizing a “smooth and respectful transition” during the ownership change, the spokesperson added. BMS did not elaborate on the financial terms of the agreement.Crucially, the news does not mean that BMS’ core innovative drugs business will cease operation in China. BMS originally linked up with China’s Sinopharm Foreign Trade to establish SASS as the first U.S.-China pharmaceutical joint venture back in 1982. When China opened its economy to foreign entities in the 1980s, multinational corporations were only allowed to enter the country through joint ventures with state-owned, local companies such as Sinopharm.BMS’ China joint venture operates a 58,000-square-meter (roughly 624,307-square-foot) manufacturing facility in Shanghai responsible for production of antibiotics, cardiovascular drugs, analgesics and metabolic medicines, according to the company’s website.BMS’ stake sale isn’t expected to disrupt facility operations or product supply in China. The transaction includes both the sale of the joint venture itself and products that SASS makes exclusively for the mainland China market, including the hepatitis antiviral Baraclude, the buffered aspirin product Bufferin, the vitamin deficiency supplement Theragran, Monopril for high blood pressure and heart failure, and Velosef, which is an antibiotic used to treat bacterial infections. Several other prescription or over-the-counter medicines are listed under the joint venture, according to a database managed by China’s National Medical Products Administration.These days, as China has become more amenable to foreign entities’ participation in the domestic market, legacy joint ventures established by Western drugmakers often maintain a mix of older drug brands, off-patent medicines and consumer products separate from the companies’ innovative therapeutics businesses.Meanwhile, BMS isn’t the only ex-China drugmaker to dispense with certain legacy brands in the country. Last August, Belgium’s UCB said it was selling its mature neurology and allergy business in mainland China to local healthcare asset manager CBC Group and the Abu Dhabi-based investment organization Mubadala in a deal worth $680 million.The deal covered the divestment of seizure drugs Keppra and Vimpat, Neupro for Parkinson’s disease and restless leg syndrome, and the allergy meds Zyrtec and Xyzal, as well as a manufacturing facility in the city of Zhuhai, located in China’s Guangdong Province.The deal was designed, in part, to free up UCB’s focus on potential innovative medicine launches across immunology, neurology and rare diseases in China, the company’s CEO, Jean-Christophe Tellier, said at the time.

AcquisitionLicense out/in

02 Dec 2024

·www.pharmaindustrial-india.com

CBC Group Acquires UCB's Mature Product Portfolio in China

CBC Group has completed the acquisition of global biopharmaceutical company UCB's mature neurology and allergy business in China, in partnership with Mubadala Investment Company, the Abu Dhabi based global investment company. The acquisition marks another successful transaction under CBC's buyout strategy of acquiring key assets from global pharmaceutical companies and a significant step in establishing a market-leading neurology company in China while expanding CBC's portfolio within the region's dynamic pharmaceutical market. The transaction, valued at USD 680 million, includes UCB's well-known brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and the Zhuhai manufacturing site. The well-established and trusted medicine portfolio will serve as an anchor asset as CBC builds out a leading integrated central nervous system (CNS) biopharma platform in China, where the market size has reached USD 33 billion. Beyond strengthening CBC's presence in the rapidly growing Chinese healthcare market, the acquisition also enhances the firm's capabilities in meeting the rising demand for neurology and allergy treatments in the wider region. In collaboration with Mubadala, CBC will tap on its proprietary investor-operator approach, deep healthcare expertise and platform synergies to drive operational efficiencies, innovation and scale to benefit more patients across the region. Fu Wei, Chief Executive Officer of CBC Group, said, "There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today's healthcare investing market. Together, we are making a profound impact on the industry by harnessing our combined expertise and capital to not only enhance patient outcomes but also build value for our stakeholders. Leveraging our joint strengths, we are poised to capitalize on synergies and deploy hands-on strategic guidance to make significant strides in CNS market access and innovation." Named 'NeuroGen Pharma', the new company embodies what CBC and Mubadala envision for neuro healthcare innovation. The company will be led by a deep and experienced management team with an extensive track record in the biopharma industry, ensuring a smooth transition to propel it into the next phase of growth. NeuroGen Pharma is expected to deliver quality treatments to a wider reach of patients and play an important role in addressing the evolving neurology treatment needs in China. The company aims to leverage innovative therapies and cutting-edge research to enhance patient outcomes and shape the future of neurology care in the region. Combined net sales for the acquired portfolio in this transaction were Euro131 million in 2023. The strategic acquisition builds on CBC's collaboration with Mubadala, which includes their investment in CBC Healthcare Infrastructure Platform's (HIP) first life science real assets venture and the joint investment in the USD 315 million fundraising round for CBC-backed Hasten, a leading pharmaceutical company. Mohamed Albadr, Head of Asia at Mubadala, said, "We are thrilled to partner with CBC Group to support the growth and development of NeuroGen Pharma as it scales to a leading entity in China and delivers transformative medicines to patients. Built on a strong foundation of proven therapies and driven by innovation and cutting-edge research, the company is uniquely positioned to address the growing need for advanced neurology and allergy treatments while aligning with our commitment to enhancing access to care and growth in the healthcare system." Jean-Christophe Tellier, CEO at UCB, said, "In the short term, UCB is exploring the launch of novel medicines in immunology, neurology, and rare diseases in China. Our dedication to serving patients with unmet needs in China remains steadfast. Building on our 28-year presence in the country, we are committed to driving patient outcomes through continued collaboration with local partners and fostering innovation. We are convinced that the CBC Group and Mubadala are the ideal partners to advance the medicine portfolio and continue to improve the lives of people living with neurology and allergy diseases in mainland China."

Acquisition

02 Dec 2024

·www.pharmaceutical-technology.com

CBC acquires UCB’s neurology and allergy business in China

The new company aims to deliver quality treatments and address evolving neurology treatment needs in the country. Credit: Volha_R/Shutterstock. CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge’s ( UCB ) mature neurology and allergy business in China for $680m. The move comes after UCB agreed to sell and license its business in August 2024. The deal encompasses UCB’s Zhuhai manufacturing site and its brands Xyzal, Keppra, Zyrtec, Vimpat and Neupro. They are set to be the cornerstone assets for CBC as it develops an integrated central nervous system (CNS) biopharma platform in China. Working alongside Mubadala, CBC plans to leverage its platform synergies, investor-operator approach and healthcare expertise, to optimise operations, foster innovation and expand its reach to benefit more patients in the region. The new entity formed from this acquisition called NeuroGen Pharma is set to offer neuro healthcare innovation services. It will be spearheaded by a management team with a solid background in the biopharma industry, which is expected to ensure a seamless transition and drive future growth. The company aims to deliver quality treatments and address the evolving neurology treatment needs in the country. The acquired portfolio reported combined net sales of €131m ($138m) in 2023. The strategic acquisition is part of a broader partnership between CBC and Mubadala, which also includes their joint investment in the $315m fundraising round for Hasten and an investment in CBC Healthcare Infrastructure Platform’s first life science real assets venture. CBC Group CEO Fu Wei stated: “There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. “This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today’s healthcare investing market.”

Acquisition

100 Deals associated with Rotigotine

External Link

KEGG	Wiki	ATC	Drug Bank
D05768	Rotigotine	N04BC09	DB05271

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Parkinson Disease	European Union	UCB Pharma SA	15 Feb 2006
Parkinson Disease	Iceland	UCB Pharma SA	15 Feb 2006
Parkinson Disease	Liechtenstein	UCB Pharma SA	15 Feb 2006
Parkinson Disease	Norway	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	European Union	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	Iceland	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	Liechtenstein	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	Norway	UCB Pharma SA	15 Feb 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Parkinson's disease	Phase 3	China	Luye Pharma Group Ltd.	11 May 2020
Kidney Failure, Chronic	Phase 3	United States	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Austria	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Finland	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	France	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Germany	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Italy	UCB BioSciences GmbH	01 Apr 2012
Gastrointestinal dysfunction	Phase 3	United States	UCB Pharma GmbH	01 Jan 2012
Dyssomnias	Phase 3	Germany	UCB Pharma GmbH	01 Nov 2004
Young onset Parkinson disease	Phase 3	Australia	UCB Pharma GmbH	01 Aug 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MDS2025	Phase 3	Parkinson Disease	294	LY03003	ctsrejtyah(napvqntlsj) = jtgidbvsgv yxwlbnzguq (xfvrrnkerd ) View more	Positive	05 Oct 2025
				Placebo	ctsrejtyah(napvqntlsj) = qjvccvhnss yxwlbnzguq (xfvrrnkerd ) View more
NCT03992196 (CTgov)	Phase 3	Restless Legs Syndrome	10	Rotigotine (Rotigotine Final Dose 2 mg/24 h)	xrfqszwbdp = ddzdrrjrgs yzloxtsdkz (gvmijiheai, ctwliudcsv - umisbnaayu) View more	-	30 Oct 2023
				Rotigotine (Rotigotine Final Dose 3 mg/24 h)	xrfqszwbdp = dxxdgljplt yzloxtsdkz (gvmijiheai, wcrkwmdewn - ukzxigmnvf) View more
NCT03728933 (CTgov)	Phase 3	Restless Legs Syndrome	23	Placebo	xouwsdtwxd(prauncbrix) = kpmudrxssu wffjdcxxaz (zvmzgqvevr, 6.8) View more	-	26 Oct 2023
NCT04571164 (NEWS) Manual	Phase 3	Parkinson Disease	294	LY03003	hizgdkbylk(esateyhwuk) = ，與安慰劑組相比，LY 03003組統一帕金森病評分量表(UPDRS)Ⅱ+Ⅲ評分較基綫顯著改善，兩組差異具有統計學意義（ P＜0.001 ）。 uuvphyweji (hwsbsskvsn ) View more	Positive	19 Jul 2022
				Placebo
NCT02365870 (ANXPD, CTgov)	Phase 4	Anxiety Disorders \| Parkinson Disease	4	rotigotine transdermal patch (Rotigotine)	hcbqgzrzqb(dtewyacumr) = emxcrgbxot rhzxotxfts (uygxoyrzvb, 0) View more	-	19 Mar 2020
				placebo (Placebo)	hcbqgzrzqb(dtewyacumr) = qwvmlktlpz rhzxotxfts (uygxoyrzvb, 5.1) View more
NCT03103919 (CTgov)	Phase 4	Parkinson Disease, Secondary \| Parkinson Disease	40	Kinesia-ONE™+Rotigotine (Rotigotine + Standard Care)	dcbfjoqomx(vaeaiukrtj) = zzwrbjqify kwgamconjx (vnhoyiowmb, brqfuuasug - pgrprhqiud) View more	-	19 Feb 2019
				Kinesia-360™+Rotigotine (Rotigotine + Standard Care + Kinesia-360™ Wearable Device)	dcbfjoqomx(vaeaiukrtj) = ibwthtamxw kwgamconjx (vnhoyiowmb, bhpyuscvbd - ttstzqezew) View more
NCT02230904 (PD0018, Pubmed \| Curr Med Res Opin) Manual	Phase 1	Parkinson Disease	57	rotigotine (Treatments A)	vzfiaofjjv(aivonvzylf) = fswsatmpxm lhrnblusch (loftqdxnam, 1.635) View more	Positive	01 Jul 2018
				rotigotine (Treatments B)	oduauwaawu(vwebtphuzy) = ourtasxpvg ifsbkoorci (abgfrfcnpm )
NCT01646255 (SP1037, Pubmed \| Parkinsonism Relat Disord) Manual	Phase 3	Parkinson Disease	346	Rotigotine	bsuwnbegkn(pzlhzssnrm): difference = -1.20 (95% CI, -1.83 to -0.57), P-Value = 0.0002 View more	Positive	01 Nov 2017
				Placebo
NCT01495793 (Pubmed \| Sleep Med)	Phase 2	Restless Legs Syndrome	24	Rotigotine transdermal system 0.5 mg/24 h	rjqbgpmqtl(etvnffvwij) = hjdhnxzwug hlpxscjvbj (idonwodxss ) View more	-	01 Apr 2017
				Rotigotine transdermal system 1 mg/24 h	rjqbgpmqtl(etvnffvwij) = cizmqngnnc hlpxscjvbj (idonwodxss ) View more
NCT01976871 (SWITCH, CTgov)	Phase 4	Restless Legs Syndrome	21	Rotigotine	gqwqlkrexy = uloweelusk jlowljmcjj (posmvcdxfb, bpqtckdffc - zygpowlbxf) View more	-	13 Oct 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Rotigotine

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation